Genital Atrophy Treatment Guide: Evidence-Based Options

You’re here for a clear, practical plan to relieve dryness, pain with sex, and urinary issues tied to genital atrophy—fast.

This guide starts with the best-proven treatments, shows what to try first, how to combine and escalate, and what it will likely cost, so you can make confident, safe decisions today.

Overview

This treatment-first overview covers the vulvar, vaginal, and lower urinary tract tissues affected by estrogen decline or antiestrogen therapies, not just menopause.

You’ll find what works (and what doesn’t), how long relief takes, safety for special situations, and how to keep results.

The short version: start with optimized lubrication and moisturizers, layer in local therapies (estrogen or DHEA) if appropriate, add pelvic floor physical therapy for pain and penetration issues, and use targeted measures to prevent UTIs.

Throughout, we summarize major guidelines and pivotal trials so you can weigh benefits and risks with your clinician.

Expect early symptom easing in weeks and peak benefit by about 8–12 weeks for most prescription options.

What counts as “genital atrophy” vs GSM, and who gets it?

Genital atrophy means thinning, dryness, and fragility of the vulvar/vaginal and nearby urinary tissues, most often from low estrogen and androgens.

Genitourinary syndrome of menopause (GSM) is the guideline term when it occurs around or after menopause. Similar changes also happen postpartum, with antiestrogen drugs, and in transmasculine patients on testosterone.

More than half of postmenopausal people experience GSM-type symptoms at some point, including dryness, pain with sex, burning, and urinary complaints such as urgency or recurrent UTIs (supported by the NAMS 2020 position statement).

“Genital atrophy treatment” therefore spans vulvar/vaginal comfort, sexual function, and urinary health.

It also includes tailored approaches for breast-cancer survivors, people breastfeeding, and those using gender-affirming hormones. Clitoral discomfort and skin microtears can be part of the same process and respond to similar local measures.

Symptoms, causes, and red flags that change the treatment plan

Your symptom pattern guides the first steps. Dryness and friction pain point to epithelial thinning and reduced lubrication. Burning and tearing suggest fragile skin and higher pH.

Deep pain with penetration often includes pelvic floor overactivity. Urgency, dysuria, and frequent UTIs reflect mucosal thinning and shifts in the vaginal and periurethral microbiome.

Hypoestrogenism is the common driver, but coexisting dermatologic conditions (like lichen sclerosus), infections, and pelvic floor disorders can mimic or compound symptoms.

Some findings change the plan or require prompt evaluation. Watch for postmenopausal bleeding, persistent lesions or ulcerations, severe focal pain, sudden changes in one area, or symptoms unresponsive to early measures.

These warrant in-person assessment to rule out dermatologic conditions, infections, or malignancy. If any red flag is present, seek care before starting or escalating home treatments.

First-line self-care foundations: lubricants and moisturizers that actually help

Start with the basics you can control now: the right lubricant for comfort during sex and a long-acting vaginal moisturizer to restore everyday hydration.

Lubricants reduce friction on contact. Moisturizers are applied regularly (not just for sex) to bind water in the tissues and reduce microtears over time.

Choose products that are gentle on the vaginal ecosystem and compatible with your protection and toys.

Selection matters. Look for a pH close to 3.8–4.5 and lower osmolality to minimize epithelial irritation (aligned with the WHO advisory on personal lubricants).

Water-based formulations are the most versatile. Silicone-based lubes are highly slick and long-lasting but can damage silicone toys. Oil-based products feel rich but can degrade latex condoms.

Start with a small amount, then reapply as needed during sex.

How to choose by symptom pattern and sensitivity

Pick ingredients for your goals and avoid common irritants. As you choose, think about your infection risk, sensitivity, and bedroom set-up.

• If you get recurrent UTIs: prefer water-based lubes with low osmolality and no added sugars; avoid glycerin if you also get frequent yeast.
• If you’re yeast-prone: avoid glycerin and heavy glycols; look for simple, fragrance-free formulas.
• If you have sensitive skin: avoid fragrances, flavors, chlorhexidine, parabens, and warming agents; patch-test on the forearm first.
• If you use latex condoms: avoid oil-based lubes (they can weaken latex); silicone or water-based are safer.
• If you use silicone toys: avoid silicone-based lubes (they can degrade toys); use water-based instead.

Moisturizers with hyaluronic acid, polycarbophil, or vitamin E can be used 2–3 times weekly to improve baseline hydration.

Expect incremental improvement over 2–4 weeks and continue even if starting prescription options.

Nonhormonal regimen if hormones are off the table

If you need a genital atrophy treatment without hormones, build a layered routine that targets comfort, tissue health, and muscle relaxation.

Combine an optimized lube, a long-acting moisturizer, pelvic floor strategies, and gentle behavior changes like extended arousal and non-penetrative intimacy while tissues heal.

This stack can deliver meaningful relief for many people, including those avoiding estrogen.

Anchor your routine with regular moisturizers and the correct lube every time you’re intimate.

Add pelvic floor relaxation (diaphragmatic breathing, warm baths, gentle external massage) and consider thermal compresses before sex to increase blood flow.

If penetration is painful, introduce a beginner dilator program and, if possible, short-term topical anesthetic (such as 2–5% lidocaine to the vestibule 10–15 minutes before sex).

Reassess at 6–8 weeks. If symptoms persist, consider local hormonal therapy or pelvic floor physical therapy.

Local hormonal therapies: vaginal estrogen, DHEA (prasterone), and ospemifene

For persistent dryness, dyspareunia, or GSM-related UTIs, local hormones are the most effective options.

Low-dose vaginal estrogen (cream, tablet, insert, or ring) directly restores the vaginal epithelium with minimal systemic absorption.

Vaginal DHEA (prasterone) converts locally to estrogens and androgens in the vaginal tissue. Ospemifene is an oral SERM that acts estrogenically in vaginal tissue but not uniformly elsewhere.

Common dosing patterns: estradiol 10 mcg tablets nightly for 2 weeks, then twice weekly; estradiol ring (7.5 mcg/day) replaced every 90 days; estradiol or conjugated estrogen creams typically 0.5 g intravaginally nightly for 2 weeks, then 2–3 times weekly.

DHEA 6.5 mg vaginal insert is used nightly. Ospemifene 60 mg is taken orally once daily.

Most people feel relief within 2–4 weeks, with peak benefit at 8–12 weeks. Side effects are usually mild (spotting, local irritation). Ospemifene carries SERM-class risks like hot flashes and rare VTE risk.

Which works better for painful sex and dryness?

Head-to-head trials are limited, but the pattern is consistent.

Low-dose vaginal estrogen shows the largest and most reliable improvements in dryness, pH, and dyspareunia, with added benefit of UTI reduction in postmenopause.

DHEA meaningfully improves dyspareunia and vaginal health indices versus placebo, particularly when estrogen is declined or contraindicated.

Ospemifene helps with dyspareunia and may suit those preferring an oral option, though it has systemic SERM effects.

If one option partially helps, layering a high-quality moisturizer and pelvic floor therapy can close the gap.

Special populations: tailored guidance you can use

Your safety profile and goals drive the plan. In each scenario below, start with nonhormonal foundations and add targeted therapies as benefits and risks allow.

Shared decision-making with your oncology, OB/GYN, or gender-affirming care team is essential when systemic risks or drug interactions are in play.

Breast-cancer survivors on aromatase inhibitors or tamoxifen

Begin with nonhormonal options (optimized lube, regular moisturizers, PFPT, dilators).

Add vaginal DHEA or low-dose vaginal estrogen only after discussing risks and preferences with your oncology team.

The ACOG clinical consensus supports cautious consideration of low-dose vaginal estrogen for refractory symptoms, especially in those on tamoxifen.

Decisions are more nuanced for aromatase inhibitor users. If used, pick the lowest effective dose and reassess at 8–12 weeks.

Transmasculine and nonbinary patients on testosterone

Testosterone can lower local estrogen, producing GSM-like vaginal dryness and pain.

Local vaginal estrogen or DHEA can relieve symptoms without undermining masculinization because systemic absorption from low-dose products is minimal.

Many patients prefer inserts or rings for discreet use. Align choices with dysphoria concerns and sexual goals, and consider PFPT if pelvic floor overactivity contributes.

Reassess at 8–12 weeks and adjust dose or route for comfort and privacy.

Postpartum and lactating individuals

Breastfeeding-related hypoestrogenism often triggers temporary vulvovaginal atrophy.

Nonhormonal care often suffices. If not, low-dose vaginal estradiol is compatible with lactation with minimal infant exposure, per LactMed: Estradiol.

For perineal healing, add gentle moisturizers and avoid irritants. Consider PFPT if there is pelvic floor pain or birth-related trauma.

Expect improvement as lactation hormones stabilize. Taper therapies as comfort returns.

Preventing recurrent UTIs tied to genital atrophy

If UTIs accompany GSM, prevention starts with restoring the vaginal epithelium and microbiome.

In postmenopausal individuals, vaginal estrogen is guideline-supported for reducing UTI recurrences by reacidifying the vagina and supporting lactobacilli (see the AUA recurrent UTI guideline).

For those needing antibiotic-sparing prevention, methenamine hippurate is a validated alternative. In the ALTAR trial, it was non-inferior to daily antibiotic prophylaxis for reducing UTI episodes (ALTAR trial).

What about supplements? A large randomized trial found D‑mannose did not significantly reduce recurrent UTIs compared with placebo (JAMA 2024).

Cranberry products have mixed evidence and may help a subset, but are less reliable than vaginal estrogen or methenamine. Reassess your plan at 3 months and after any breakthrough infections.

Pelvic floor physical therapy and vaginal dilators

When penetration hurts, pelvic floor muscles often guard and tighten. This worsens pain and reduces arousal-induced lubrication.

Pelvic floor physical therapy (PFPT) can downtrain overactive muscles, improve blood flow, and normalize touch. It pairs well with moisturizers and local hormones to address both tissue and muscle drivers of dyspareunia.

A typical starter approach includes diaphragmatic breathing and gentle external pelvic floor release. Progress to small, well-lubricated dilators for 5–10 minutes, most days, without pushing through pain.

PFPT sessions (often every 1–2 weeks for 6–10 visits) add biofeedback, manual techniques, and a home program. Plan to reassess at 6–8 weeks; early wins usually show as easier initial penetration and reduced burning.

Energy devices and PRP: what the evidence and regulators say

CO2 or Er:YAG laser and radiofrequency devices are marketed for “vaginal rejuvenation,” but evidence quality is limited and long-term safety is uncertain.

The FDA has cautioned against unproven claims for GSM and sexual function, noting risks of burns, scarring, and pain.

Small studies report symptom improvements, but many lack controls or have short follow-up.

Consider energy devices only after optimizing guideline-backed therapies or when hormones are clearly contraindicated. Seek experienced clinicians who discuss realistic outcomes and risks.

Platelet-rich plasma (PRP) for vulvovaginal symptoms also lacks robust, controlled data. Expect out-of-pocket costs, and trial conservative options first.

Stepwise treatment algorithm and timelines to relief

Use this sequence to start, combine, and escalate care based on symptom severity and safety. Most people feel improvements within weeks; local hormonal therapies typically reach maximum benefit in 8–12 weeks.

• Mild dryness or irritation: choose a low-osmolality, pH-appropriate water-based lube for sex; add a polycarbophil or hyaluronic acid moisturizer 2–3 times weekly.
• Dyspareunia or recurrent microtears: add low-dose vaginal estrogen (or vaginal DHEA if estrogen-avoidant); continue moisturizers and use lube generously; defer or modify penetration while healing.
• Pelvic floor-mediated pain: add PFPT and a gentle dilator program; consider short-term topical lidocaine to the vestibule before intimacy.
• Recurrent UTIs: in postmenopause, prioritize vaginal estrogen; if infections persist, discuss methenamine hippurate; review technique and lube choice.
• Partial response at 8–12 weeks: adjust dose/route, switch from cream to tablet/ring or to DHEA/ospemifene, and ensure PFPT is engaged if penetration is a goal.

Reassess regularly and step down only after symptoms are stable for several months. Many will need ongoing maintenance (for example, twice-weekly estrogen or DHEA plus moisturizers).

Monitoring, follow-up, and when to escalate or refer

Track progress so you know what’s working. Keep a brief weekly log of dryness (0–10), pain with sex (0–10), and UTI episodes. Some people add home vaginal pH testing to confirm reacidification with local estrogen.

In clinic, your clinician may use tools like the Vaginal Health Index or GSM symptom scores to quantify changes over time.

Follow up at 8–12 weeks after starting or changing therapy, then every 6–12 months on maintenance.

Refer or escalate if you have persistent dyspareunia despite PFPT and local therapy, recurrent UTIs despite estrogen and methenamine, suspected lichen sclerosus or other dermatoses, postmenopausal bleeding, unexplained lesions, or severe pelvic pain.

Urogynecology, menopause specialists, pelvic floor PT, and dermatology can each address specific barriers to recovery.

Costs, access, and coverage: making treatment affordable

Plan for costs upfront so you can stick with what works. OTC lubricants typically run $8–20 per bottle.

Long-acting moisturizers are about $10–30 per month. Generic estradiol creams and 10 mcg tablets often cost $20–80 per month with coupons, while estradiol rings and brand-name inserts may be $90–200 per 90 days depending on insurance.

Vaginal DHEA (prasterone) typically costs $150–250 per month. Ospemifene ranges roughly $150–400 per month.

PFPT visits are often $100–200 per session before insurance. Dilator sets are about $40–100.

Energy devices (CO2/Er:YAG laser or RF) usually cost $1,500–3,000 for a series, often not covered.

To lower Rx costs, ask about generics, 90-day supplies, prior authorizations, and manufacturer coupons. Pharmacists can help you compare equivalent strengths and routes.

Safety, interactions, and contraindications

Choose and combine treatments with your medical history in mind. Low-dose vaginal estrogen has minimal systemic absorption and is considered safe for most, including many with complex histories, when chosen thoughtfully with a clinician.

DHEA is locally acting but still warrants shared decision-making in estrogen-sensitive conditions.

• SERMs such as ospemifene can increase the risk of venous thromboembolism and hot flashes; avoid with active or high-risk VTE histories and discuss endometrial monitoring if bleeding occurs.
• Avoid initiating any estrogen therapy with unexplained vaginal bleeding; evaluate first.
• Drug/product interactions: oil-based lubes degrade latex condoms; silicone lubes can damage silicone toys; check packaging and choose accordingly.
• With aromatase inhibitors or tamoxifen, involve oncology early and consider nonhormonal options first; if local estrogen is used, pick the lowest effective dose and monitor response.

FAQs

• What’s the difference between genital atrophy, vaginal atrophy, and GSM—and which term applies to my symptoms?
  All three describe thinning and dryness from low hormones; “GSM” is the guideline term for these vulvovaginal and urinary symptoms in peri/postmenopause. If your dryness, pain with sex, or urinary urgency started after menopause, with antiestrogens, postpartum, or on testosterone, you likely fit this spectrum. Treatment choices are similar and tailored to your cause and goals.

• How do I choose the safest and most effective lubricant for recurrent UTIs or yeast infections?
  Pick a water-based lube with low osmolality and pH near 3.8–4.5, without glycerin or fragrances if you’re yeast‑prone. Avoid oil-based lubes with latex condoms and silicone lubes with silicone toys. For UTIs, pair the right lube with daily moisturizers and, if postmenopausal, consider vaginal estrogen to reduce recurrences.

• Which works better for painful sex: vaginal estrogen, DHEA (prasterone), or ospemifene?
  Vaginal estrogen often has the most consistent, largest effect on dryness and dyspareunia, with peak relief in 8–12 weeks. DHEA improves dyspareunia and tissue health when estrogen isn’t preferred, while ospemifene is an oral option with SERM-class considerations. Many patients start with local estrogen, then personalize based on response and safety.

• Is low-dose vaginal estrogen safe if I’m on an aromatase inhibitor after breast cancer?
  It can be considered for refractory symptoms after trying nonhormonal options, but decisions should be shared with your oncology team. Use the lowest effective dose and reassess regularly.

• Does testosterone therapy in trans men cause genital/vaginal atrophy, and how is it treated without affecting masculinization?
  Yes—testosterone lowers local estrogen, producing GSM-like dryness and pain. Low-dose vaginal estrogen or DHEA can relieve symptoms with minimal systemic absorption, and most patients do not notice changes in masculinization. Choose discreet routes (e.g., inserts or rings) and combine with PFPT if penetration is a goal.

• How soon will treatments start working, and what happens if I stop them—will symptoms return?
  Lubricants help immediately; moisturizers help within 2–4 weeks. Vaginal estrogen and DHEA typically ease symptoms in 2–4 weeks, peaking by 8–12 weeks. If you stop local hormones or moisturizers, tissues often regress within weeks to months; plan on maintenance (e.g., twice weekly) to sustain relief.

• Are energy-based treatments like CO2 laser worth the cost compared with prescription options?
  Most people improve with moisturizers, local hormones, and PFPT at far lower cost and with better evidence. Consider devices only after optimizing proven therapies and with full discussion of risks and costs.

• What nonhormonal regimen can I use if hormones are contraindicated for me?
  Use a low‑osmolality, pH-appropriate lube for sex; a long-acting moisturizer 2–3 times weekly; PFPT and a gentle dilator program for pain; and behavioral strategies (longer arousal, gradual penetration). If UTIs recur, ask about methenamine hippurate; for pain flares, topical lidocaine to the vestibule can help before sex.

• Can vaginal estrogen reduce recurrent UTIs and by how much?
  Yes—by restoring a healthy, lactobacillus‑dominant, low‑pH environment. Clinical guidelines recommend it for postmenopausal recurrent UTIs, and studies show meaningful reductions in recurrence rates over months of use. Combine with hydration, timed voiding, and correct lube/moisturizer choices.

• What are typical out-of-pocket costs for vaginal estrogen, DHEA, ospemifene, and laser treatments?
  Generics for vaginal estrogen are often $20–80/month with coupons; rings or brand inserts may be $90–200 per 90 days. DHEA is about $150–250/month; ospemifene $150–400/month. Laser or RF series typically cost $1,500–3,000 and are usually not covered. Ask about generics, 90‑day fills, and prior authorizations.

• How do pelvic floor physical therapy and vaginal dilators help, and how do I start safely?
  PFPT reduces muscle guarding, restores blood flow, and retrains your pain response; dilators build comfortable tolerance to stretch. Start with diaphragmatic breathing and a small, well-lubricated dilator for 5–10 minutes most days, stopping well before pain. Pair with moisturizers and, if needed, topical lidocaine; expect early gains in 4–6 weeks.